ValiRx Plc Company Profile (LON:VAL)

About ValiRx Plc (LON:VAL)

ValiRx Plc logoValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits. Its product pipeline includes VAL101, VAL201, VAL401 and Nav3. VAL201 is an anti-cancer therapeutic drug, which is in clinical trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth including endometriosis. VAL401 is the reformulation of a generic drug for treatment of a chronic non-oncology disease in an oral capsule. VAL101 is a therapeutic based on its Gene Inactivation by chromatin engineering (GeneICE) platform. NAV3 Cancer Screening Test enables the detection of cancer cells in tissue samples. It operates through divisional companies, including ValiPharma, ValiFinn and ValiSeek.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: LON:VAL
  • CUSIP: N/A
  • Web: N/A
  • Market Cap: £1.33 million
  • Outstanding Shares: 57,743,000
Average Prices:
  • 50 Day Moving Avg: GBX 2.28
  • 200 Day Moving Avg: GBX 4.32
  • 52 Week Range: GBX 2.06 - GBX 11.49
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: GBX 0.04 per share
  • Price / Book: 0.58
  • EBIDTA: ($4,070,000.00)
  • Average Volume: 1.64 million shs.

Frequently Asked Questions for ValiRx Plc (LON:VAL)

What is ValiRx Plc's stock symbol?

ValiRx Plc trades on the London Stock Exchange (LON) under the ticker symbol "VAL."

Where is ValiRx Plc's stock going? Where will ValiRx Plc's stock price be in 2017?

1 brokerages have issued 1 year target prices for ValiRx Plc's shares. Their predictions range from GBX 6.50 to GBX 6.50. On average, they anticipate ValiRx Plc's stock price to reach GBX 6.50 in the next twelve months. View Analyst Ratings for ValiRx Plc.

Who are some of ValiRx Plc's key competitors?

How do I buy ValiRx Plc stock?

Shares of ValiRx Plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

How much does a share of ValiRx Plc stock cost?

One share of ValiRx Plc stock can currently be purchased for approximately GBX 2.30.

Analyst Ratings

Consensus Ratings for ValiRx Plc (LON:VAL) (?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: GBX 6.50

Analysts' Ratings History for ValiRx Plc (LON:VAL)
DateFirmActionRatingPrice TargetDetails
5/15/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 6.50View Rating Details
12/8/2016Northland SecuritiesReiterated RatingCorporateView Rating Details
11/5/2015Northland Capital PartnersReiterated RatingcorporateView Rating Details
(Data available from 5/23/2015 forward)


Earnings History for ValiRx Plc (LON:VAL)
No earnings announcements for this company have been tracked by


Earnings Estimates for ValiRx Plc (LON:VAL)
Current Year EPS Consensus Estimate: $0.00 EPS


Dividend History for ValiRx Plc (LON:VAL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for ValiRx Plc (LON:VAL)
No insider trades for this company have been tracked by


Headline Trends for ValiRx Plc (LON:VAL)
Latest Headlines for ValiRx Plc (LON:VAL)
DateHeadline logoValiRx Plc (VAL) Rating Reiterated by Beaufort Securities - May 8 at 7:05 AM logoCompany Overview of Azure Holdings plc - March 28 at 9:09 PM logoValiRx Plc (VAL) Receives Speculative Buy Rating from Beaufort Securities - March 16 at 2:30 AM logoVAL. With Val 401 d- - March 9 at 4:08 AM logoValiRx Says "Significant" Progression Made With VAL401 Trial - March 9 at 4:08 AM logoValiRx Shares Drop On Discounted Placing To Progress Trial Development (ALLISS) - March 3 at 5:11 AM logoGlobal Endometriosis Industry - February 27 at 5:19 PM logoValiRx Takes More Funds From Loan Facility To Progress Trials - December 3 at 9:37 AM logoValiRx Makes Progress With Second Clinical Testing Site For VAL401 - December 2 at 10:28 AM


ValiRx Plc (VAL) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by Staff